Expert Interview
Understand early perceptions UCB's UCB0022 asset for the treatment of Parkinson's Disease.
Ticker(s): UCB.XBRU, UCBJF, UNC.XFRA, 0NZT.XLONInstitution: University of Louisville
- Professor of Neurology, Medical Geneticist, Endowed Chair of Parkinson’s Disease Research, & Director, Movement Disorders Program at University of Louisville.
- Manages 90 patients with Huntington's disease and 35 patients with Friedreich’s Ataxia.
- Research interests are focused on understanding the underlying genetic basis of hereditary spastic paraplegia and essential tremor; clinical interests include surgical therapies for Parkinson's disease, essential tremor and dystonia, and botulinum toxin procedures for dystonia and spasticity.
What is your opinion of UCB's phase 2 endpoints, which are presumed to focus on off-time PD symptoms? Is there enough clinical interest/demand for an asset to be focused on Off-time symptoms versus On-Time and dyskinesia?
Given the currently available information on UCB0022, is there enough data to create interest in the PD community for an asset that is predominately focused on Off-Time PD symptom treatment? What would be your expectation for the needed phase 2 data to make you interested in understanding more about UCB0022? What type of data would be required / expected to make you interested in potentially incorporating this asset into a treatment protocol?
Why do you think that UCB is not focused on measuring dyskinesia (e.g. UDysRS) in the phase 2 study? Do you think future studies will be required to focus on measuring dyskinesia (e.g. UDysRS)?
Added By: pharmaadvisorWhat are the perceptions your perceptions of UCB0022 Phase 1 data in healthy participants and patients with PD and subsequent enthusiasm for UCB002 in advanced PD?
Added By: pharmaadvisorWhat are potential concerns that you might have for this asset completin g phase 2 and heading into a potential phase 3 program?
Added By: pharmaadvisorAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
